Cite
Abstract 1267: Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas
MLA
Ulrike Philippar, et al. “Abstract 1267: Combination Therapy of JNJ-67856633, a Novel, First-in-Class MALT1 Protease Inhibitor, and JNJ-64264681, a Novel BTK Inhibitor, for the Treatment of B-Cell Lymphomas.” Cancer Research, vol. 81, July 2021, p. 1267. EBSCOhost, https://doi.org/10.1158/1538-7445.am2021-1267.
APA
Ulrike Philippar, Lorena Fontan, Ivo Cornelissen, Haopeng Rui, Sriram Balasubramanian, Marcello Gaudiano, Mariette Bekkers, Luc Van Nuffel, Tianbao Lu, John Wiener, Mark Tichenor, Tony Greway, Kathryn Packman, Bie Verbist, Yusri Elsayed, Ricardo Attar, Jacqueline Bussolari, & John Gerecitano. (2021). Abstract 1267: Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas. Cancer Research, 81, 1267. https://doi.org/10.1158/1538-7445.am2021-1267
Chicago
Ulrike Philippar, Lorena Fontan, Ivo Cornelissen, Haopeng Rui, Sriram Balasubramanian, Marcello Gaudiano, Mariette Bekkers, et al. 2021. “Abstract 1267: Combination Therapy of JNJ-67856633, a Novel, First-in-Class MALT1 Protease Inhibitor, and JNJ-64264681, a Novel BTK Inhibitor, for the Treatment of B-Cell Lymphomas.” Cancer Research 81 (July): 1267. doi:10.1158/1538-7445.am2021-1267.